Background/Aim: The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclinical antitumor activity. To determine the maximum tolerated dose or a recommended dose, and to delineate the pharmacokinetic profile of LFA102 in Japanese patients, we conducted a phase I study. Patients and Methods: LFA102 was intravenously infused every 4 weeks to patients with advanced breast or castration-resistant prostate cancer, and the dose increased from 3 to 40 mg/kg. Results: Fourteen patients were treated, and toxicities were reported in 9 (64%) patients. They were all grade 1 or 2, and the most frequently observed toxicity was nausea (3 patients, 21%). No dose-limiting toxicities were observed. LFA102 did not show antitumor activity as a single agent. Conclusion: Treatment with LFA102 was well tolerated. Prolactin mediates its physiological effects through interactions with the prolactin receptor (PRLR). Following binding to PRLR, prolactin activates a wide array of downstream signals, including JAK2/STAT5, JAK1/STAT3, SRC, and FAK pathways leading to PI3K/AKT and RAF/MEK/ERK activation. These signaling cascades trigger cell proliferation, survival, migration, differentiation, and angiogenesis (1). Preclinical data show that mammary gland-or prostate-specific expression of prolactin in transgenic mice increases the incidence of breast and prostate tumors, respectively (2-4). In the clinic, PRLR overexpression is observed in many malignancies, including breast, prostate, ovarian, colorectal, and pancreatic cancers (5-8). Indeed, 95% of breast and prostate cancers are PRLR-positive (9, 10) and high levels of prolactin in the blood have been correlated with increased risk and poor prognosis in breast cancer (11-13). In prostate cancer, prolactin expression has been correlated with phosphorylation of Stat5 (a key mediator of prolactin signaling), high Gleason scores and unfavorable prognosis (14, 15). Prolactin protein is synthesized and secreted from the pituitary gland and from extrapituitary sites including breast and prostate tissues. The overexpression of PRLR in breast and prostate cancers stimulates their growth and contributes to their aggressiveness by autocrine and paracrine mechanisms (3, 16, 17). Furthermore, endogenous prolactin increased the constitutive tyrosine phosphorylation of HER2 in a breast cancer cell line, leading to enhanced growth through the RAS-MAPK pathway (18). Therefore, targeting the prolactin signaling pathway is an attractive endocrine therapeutic strategy. LFA102 is a humanized IgG1/ĸ monoclonal antibody (mAb) against PRLR. The antibody neutralizes all prolactin-induced intracellular signaling pathways examined in vitro, including those mediated through Stat5, Akt, and Erk1/2. Furthermore, LFA102 induces antibody-dependent cell-mediated cytotoxicity in vivo, and inhibits the growth of prolactin-dependent cell lines engineere...